A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

Sponsor
Novo Nordisk A/S
Study ID
NCT07121153
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC0487-0111 A — DRUG
    Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
  • Placebo A — DRUG
    Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.

Study Details

The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2. The aim of the study is to see how safe the study medicine is and how it behaves in human body. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) and which treatment they get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors but has previously been tested in humans. This study will last for up to 53 days.

Key Dates

Start date
Aug 11, 2025
Status verified
Feb 2026
Primary completion
Dec 20, 2025
Completion
Dec 20, 2025

Study Design

Enrollment
36 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A1
    Cohort A1 will include 12 participants randomised (3:1), with 9 participants being randomised to receive a single dose level 1 of active treatment and 3 participants randomised to receive placebo.
  • Experimental: Cohort A2
    Cohort A2 will include 12 participants randomised (3:1), with 9 participants being randomised to receive a single dose level 2 of active treatment and 3 participants randomised to receive placebo.
  • Experimental: Cohort A3
    Cohort A3 will include 12 participants randomised (3:1), with 9 participants being randomised to receive a single dose level 3 of active treatment and 3 participants randomised to receive placebo.

Primary Outcome Measure

Number of treatment emergent adverse events (TEAEs) [ Time Frame: From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23) ]

Related Studies